Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…Abstract Number: 0430 • ACR Convergence 2021
Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
Background/Purpose: Despite treatment advances, ANCA-associated vasculitis (AAV) remains associated with excess morbidity and mortality. Interstitial lung disease (ILD) is an increasingly recognized manifestation of AAV…Abstract Number: 1868 • ACR Convergence 2021
Neutrophil Extracellular Trap Formation in Patients with Vasculitis
Background/Purpose: Neutrophil extracellular trap (NET) formation, the extrusion of chromatin and granular components from activated neutrophils, is essential in host defense. However, NET formation has…Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…Abstract Number: 0414 • ACR Convergence 2021
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…Abstract Number: 0433 • ACR Convergence 2021
Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
Background/Purpose: Co-prescribing mesna with CYC for AAV aims to prevent the potential urotoxic effects of CYC. We investigated current clinical practice related to prescribing mesna…Abstract Number: 0415 • ACR Convergence 2021
Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) causes sinus symptoms that impact quality of life. The 22-item Sinonasal Outcome Test (SNOT-22) is a patient-reported outcome measure to assess…Abstract Number: 0434 • ACR Convergence 2021
Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is considered a chronic relapsing condition, with unknown etiology. This study was undertaken to gain insight to the…Abstract Number: 0417 • ACR Convergence 2021
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…Abstract Number: 0435 • ACR Convergence 2021
Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071
Background/Purpose: Anti-neutrophil cytoplasm antibodies (ANCA) are immunoglobulin G (IgG) autoantibodies directed against constituents of primary neutrophil granules (Davies, Moran et al. 1982). There is strong…Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…Abstract Number: 0436 • ACR Convergence 2021
Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Background/Purpose: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a systemic autoimmune condition caused by granulomatous inflammation of small and medium arteries, arterioles…Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »